Abstract
Get full access to this article
View all access options for this article.
References
1.
Fricchione G
,
Bush G
,
Fozdar M
.Recognition and treatment of the catatonic syndrome .J Intensive Care Med . 1997 ;12 :135 -147
2.
2.CaroffSNMannSCKeckPEJr.Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry (in press)
3.
Caroff SN
,
Mann SC.
.Neuroleptic malignant syndrome .Med Clin N Am . 1993 ;77 :185 -202
4.
Mann SC
,
Caroff SN
,
Lazarus A.
.Pathogenesis of neuroleptic malignant syndrome .Psychiatric Ann . 1991 ;21 :175 -180
5.
Sakkas P
,
Davis JM
,
Hua J
.Pharmacotherapy of neuroleptic malignant syndrome .Psychiatric Ann . 1991 ;21 :157 -164
6.
Rosenberg MR
,
Green M.
.Neuroleptic malignant syndrome; review of response to therapy .Arch Intern Med . 1989 ;149 :1927 -1931
7.
Shalev A
,
Hermesh H
,
Munitz H.
.Mortality from neuroleptic malignant syndrome .J Clin Psychiatry . 1989 ;50 :18 -25
8.
Yamawaki S
,
Yano E
,
Uvchitomi Y.
.Analysis of 497 cases of neuroleptic malignant syndrome in Japan .Hiroshima J Anesth . 1990 ;26 :35 -44
9.
Rosebush PI
,
Stewart T
,
Mazurek MF.
.The treatment of neuroleptic malignant syndrome .Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry . 1991 ;159 :709 -712